Bamlanivimab_targeted_S-gene_sequencing
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA859660
下载链接
链接失效反馈官方服务：
资源简介：
As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), non-hospitalized participants with symptomatic SARS-CoV-2 infection were given bamlanivimab (700mg or 7000mg) or placebo treatment. We performed targeted Spike (S) gene next-generation sequencing to detect bamlanivimab resistance mutations. Using this data, we can assess whether in vivo emergence of SARS-CoV-2 resistance mutations alters viral replication dynamics or therapeutic efficacy in the immune-competent population.
创建时间：
2022-07-18
